What is this event about?
|
|
About the conference
This year, SMi offers its 2nd annual conference COPD: Novel Therapeutics and Management Strategies. COPD was the 6th biggest killer in the world in 1990, and is forecast to be the 4th biggest killer by 2030. At present, one person every 15 seconds dies of COPD worldwide. In the Western world, it is the only major cause of death that is on the increase. Despite this, COPD tends to be neglected in terms of drug discovery & development when compared to Asthma.
Taking place in Munich, Germany, this conference will look at the latest in R&D, partnering options and drug development strategies for developing novel therapeutics for COPD. It will also focus on the challenges of developing a successful COPD pipeline, on opportunities for addressing COPD in Asia and on COPD management strategies.
The conference aims to address the imbalance in research and industry focus between Asthma and COPD, and place the spotlight firmly on COPD alone.
Why not attend the associated workshop as well?
Associated with the conference there will be a half-day interactive workshop on "Drugs and Devices and Inhalation Therapy", taking place on 16th November. It will cover inhaled treatments for COPD, with a particular focus on the design of clinical trials and on techniques and devices for inhaled therapeutics. This will be led by Sabine Häußermann, Director of Business Development, Inamed Research. To see more information about the workshop, please see the COPD 2010 workshop page.
Keen to see the detailed programme? Click here.
Want to download the brochure? Click here.
Register for the event here!
Group discounts available - click here
Fancy speaking at the conference? Do you know of anyone who may be interested in speaking? We are always on the look-out for new speakers for our upcoming conferences. Let us know: contact the Conference Producer.
For sponsorship and exhibitioning opportunities, contact our Sponsorship Department
|
Why should you attend this event?
Why should you attend this event?
|
What you will learn about
- Developing novel therapeutics: various perspectives on the best strategies to develop new COPD therapeutics and build a successful COPD pipeline
- New approaches and new targets: the latest developments in R&D
- Clinical studies for COPD: proof of concept studies and innovative design of trials to optimise success in developing new COPD treatments
- Biomarkers: identifying and developing biomarkers for COPD
- Animal models: the relevance and limitations of the latest animal models
|
 |
 |
How you will benefit
Examine the current state of the market for COPD therapeutics
Discover the latest research and technologies
Study the different approaches being taken to develop new COPD treatments
Network with leaders from business and research in the COPD field
|
Hear keynote addresses from:
Who is chairing this event?
|
Day One
Christopher Meade
Head Global Licensing Respiratory
Boehringer Ingelheim
|
Day Two
Michael R. Hodges
Chief Medical Officer
Altair Therapeutics
|
Who is speaking at this event?
|
Our keynote speakers
Alasdair Gaw
Director of Translational Science, Respiratory and Inflammation
AstraZeneca
Paolo Renzi
Chief Medical Officer
Topigen
Christopher Meade
Head Global Licensing Respiratory
Boehringer Ingelheim
Donna Finch
Principal Scientist, Respiratory, Inflammation and Autoimmunity
MedImmune
Nigel Dallow
Director of Statistics, Discovery Biometrics Respiratory
GlaxoSmithKline
Birgit Jung
Director, Pulmonary Diseases Research
Boehringer Ingelheim
|
Our expert speakers also include
Deborah Hartman, Vice President, Respiratory & Inflammation Research, AstraZeneca
Nestor Molfino, Vice President Clinical Development, Head Respiratory Diseases, MedImmune
Alexis Rames, Translational Medicine Leader, Inflammation/Respiratory Early Development, Roche
Liz Hardaker, Research Investigator I, Novartis
Athula Herath, Statistical Director, MedImmune
Antonio Nardi, Associate Scientific Director, Grünenthal
Idelle Weisman, Medical Director - Respiratory, Pfizer
Marlin Carlsson, Research Physician RITA, AstraZeneca
Daniel Bock, Director Preclinical and Clinical R&D, Revotar
Wolfgang Meyer-Sabellek, Chief Medical Officer, Revotar
Alan Young, Associate Director & Principal Scientist, AstraZeneca
Zorica Zivkovic, Associate Professor in Paediatrics, Medical Academy-US Medical School, Belgrade, Serbia
To see the full agenda for the event, click here.
|
Who should attend?
Who should attend this event?
|
Chief Executives, Executive Directors, Vice Presidents, Heads, Senior Scientists, Team leaders of
- COPD
- Respiratory Therapeutic Area
- Respiratory Science
- Respiratory Technology
- Global Product Advocacy (Respiratory)
- Research & Development
- Inflammation
- Allergy and Respiratory
- Global Discovery Medicine
- Global Medical Science
- Clinical Therapy Area
- Respiratory & Inflammation Therapeutic area
- Respiratory Medical Affairs
- Clinical Research and Development
- Clinical & Regulatory Affairs
- Drug Discovery
- Drug Delivery
- Inhalation Drug Delivery
- Preclinical Development
|
Delegates at our 2009 COPD conference came from across the world
|
Venue details
Munich's only hotel with a direct 35-minute train link to the airport, the Hilton Munich City hotel is adjacent to the Gasteig Cultural Centre. Do business in the Executive Lounge, de-stress in the gym then dine on specialty meatloaf at Löwenschänke restaurant. The city centre is just a 10-minute walk away.
Book your accommodation at SMi discounted rates by calling us on +44 (0)870 9090 713, sending a fax to +44 (0)870 9090 714 or emailing hotels@smi-online.co.uk
Conference Documentation
Transcription CD ROM
SMi is pleased to announce the Transcription CD ROM
What does it include?
- - The latest presentations from each expert speaker
- - Carefully transcribed speaker documentation in PDF format
- - Convenience of having information in text for ease of reference
Please Note: If would prefer not to receive this service you can opt out by e-mailing cservices@smi-online.co.uk. A fee of £100 will be deducted from your purchase.
|
Events Home Page
